{"nctId":"NCT01646021","briefTitle":"Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy","startDateStruct":{"date":"2012-12-10","type":"ACTUAL"},"conditions":["Mantle Cell Lymphoma"],"count":280,"armGroups":[{"label":"Ibrutinib","type":"EXPERIMENTAL","interventionNames":["Drug: Ibrutinib"]},{"label":"Temsirolimus","type":"EXPERIMENTAL","interventionNames":["Drug: Temsirolimus"]}],"interventions":[{"name":"Ibrutinib","otherNames":[]},{"name":"Temsirolimus","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Confirmed diagnosis of mantle cell lymphoma (MCL)\n* Received at least 1 prior rituximab-containing chemotherapy regimen (separate lines of therapy are defined as single or combination therapies that are either separated by disease progression or by a \\> 6 month treatment-free interval)\n* Documented relapse or disease progression following the last anti-MCL treatment\n* At least 1 measurable site of disease according to Revised Response Criteria for Malignant Lymphoma\n* Eastern Cooperative Oncology Group performance status grade 0 or 1\n* Protocol-defined hematology and biochemistry laboratory values\n\nExclusion Criteria:\n\n* Prior nitrosoureas within 6 weeks, chemotherapy within 3 weeks, therapeutic anticancer antibodies within 4 weeks, radio- or toxin-immunoconjugates within 10 weeks, radiation therapy or other investigational agents within 3 weeks, or major surgery within 4 weeks of randomization\n* Prior treatment with temsirolimus, other mTOR inhibitors, ibrutinib, or other Bruton's tyrosine kinase (BTK) inhibitors\n* Known central nervous system lymphoma\n* Received an allogeneic or autologous hematopoietic stem cell transplant \\<=6 months from the date of randomization and on immunosuppressive therapy or have evidence of active graft versus host disease\n* Diagnosed or treated for malignancy other than MCL, except: malignancy treated with curative intent and with no known active disease present for \\>=3 years before randomization, adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease, adequately treated cervical carcinoma in situ without evidence of disease\n* History of stroke or intracranial hemorrhage within 6 months prior to randomization\n* Requires anticoagulation with warfarin or equivalent vitamin K antagonist\n* Requires treatment with strong CYP3A inhibitor\n* Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification\n* Known history of human immunodeficiency virus (HIV) or active hepatitis C virus (HCV) or active hepatitis B virus (HBV) infection or any uncontrolled active systemic infection requiring intravenous antibiotics\n* Woman who is pregnant or breast-feeding\n* Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the patient's safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival (PFS)","description":"PFS is defined as the duration in months from the date of randomization to the date of progression disease (PD) or relapse from complete response (CR) or death whichever was reported first and was assessed based on the investigator assessment. Revised Response Criteria for Malignant Lymphoma categorizes the response of the treatment of a patient's tumour to CR (the disappearance of all evidence of disease), Relapsed Disease or PD (Any new lesion or increase by greater than or equal to \\[\\>=\\] 50 percent \\[%\\] of previously involved sites from nadir).","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.6","spread":null},{"groupId":"OG001","value":"6.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response Rate (ORR)","description":"ORR is defined as the percentage of participants who achieved either CR or PR as best overall response based on the investigator assessment. CR is Disappearance of all target lesions while PR is greater than or equal to 30 % decrease in the sum of the longest diameter of target lesions and Overall Response (OR) is sum of CR and PR.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.0","spread":null},{"groupId":"OG001","value":"46.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"Overall survival (OS) was defined as the interval between the date of randomization and the date of death from any cause.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.3","spread":null},{"groupId":"OG001","value":"23.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response","description":"Duration of response (CR or PR), defined as the duration in days from the date of initial response to the date of first documented evidence of progressive disease (or relapse for participants who experience CR during the study) or death. The analysis was based on the investigator assessment.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.1","spread":null},{"groupId":"OG001","value":"6.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Time-to-Next Treatment","description":"Time to next treatment was measured from the date of randomization to the start date of any anti-neoplastic treatment subsequent to study treatment.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.8","spread":null},{"groupId":"OG001","value":"11.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival 2","description":"Progression-free survival 2 defined as the time interval between the date of randomization and date of event, defined as progressive disease as assessed by investigator that started after the next line of subsequent anti-neoplastic therapy (including cross-over to ibrutinib), death from any cause, or the start of the second subsequent anti-neoplastic therapy if no progressive disease was recorded after the first subsequent anti-neoplastic therapy.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.2","spread":null},{"groupId":"OG001","value":"15.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Worsening in the Lymphoma Sub Scale of Functional Assessment of Cancer Therapy- Lymphoma (FACT-Lym)","description":"Time to worsening in the Lymphoma subscale of the FACT-Lym, defined as the interval from the date of randomization to the start date of worsening. Worsening was defined by a 5-point decrease from baseline. FACT-Lym Lymphoma subscale contains 15 questions, scores from 0 to 4 for each question (higher the worse). Lymphoma subscale score is the total of reverse scores, range 0 to 60. Higher scores indicate a better quality of life.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"10.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Affected With Treatment-emergent Adverse Events","description":"An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"139","spread":null},{"groupId":"OG001","value":"138","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Time to Response","description":"Time to response for participants with CR/PR, defined as the interval between the date of randomization and date of initial documentation of response.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.15","spread":null},{"groupId":"OG001","value":"2.14","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Extent of Exposure of Time","description":"Extent of exposure is defined as the duration of the treatment administered during the study. Duration of exposure is calculated as the number of months between the start and end of treatment.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.39","spread":null},{"groupId":"OG001","value":"3.02","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"One Year Survival Rate","description":"One -year survival rate, defined as the proportion of participants who were alive 1 year after randomization.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.68","spread":null},{"groupId":"OG001","value":"0.61","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Area Under the Plasma Concentration of Ibrutinib During Steady State (AUC-ss)","description":"The AUC-ss is the area under the plasma concentration time curve observed during steady state.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"561.6","spread":"448"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Biomarkers That Alter B-cell Receptor (BCR) Signaling or Activate Alternative Signaling Pathways and to Explore Their Association With Response or Resistance to Ibrutinib","description":"Biomarker evaluations to identify markers altering BCR signaling or activate alternative signaling pathways and explore their association with response or resistance to ibrutinib. Next-generation sequencing at baseline identifies possible primary resistance mutations and those found only at progression are acquired mutations on therapy.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Hospitalizations Reported Related Medical Resource Utilization Information (MRUI)","description":"Medical resource utilization data associated with medical encounters related to disease was reported for all participants throughout the study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"4.6"},{"groupId":"OG001","value":"2.8","spread":"4.3"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Emergency Room Visits Reported Related Medical Resource Utilization Information (MRUI)","description":"Medical resource utilization data associated with medical encounters related to disease was reported for all participants throughout the study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"0.4"},{"groupId":"OG001","value":"1.2","spread":"0.4"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Days of Hospitalization and Emergency Room Visits Reported Related Medical Resource Utilization Information (MRUI)","description":"Medical resource utilization data associated with medical encounters related to disease was reported for all participants throughout the study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.7","spread":"20.5"},{"groupId":"OG001","value":"20.3","spread":"22.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"1.3"},{"groupId":"OG001","value":"1.6","spread":"1.3"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"The Mean Change From Baseline in Euro QoL Five-Dimension (EQ-5D-5L) Scores for Each Post Baseline Assessment","description":"The EQ-5D is a participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression, using 5 levels (1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and possible total score range -0.594 to 1; higher score indicates a better health state.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"0.2"},{"groupId":"OG001","value":"0.7","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.2"},{"groupId":"OG001","value":"0.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.2"},{"groupId":"OG001","value":"-0.1","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.2"},{"groupId":"OG001","value":"0.0","spread":"0.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.2"},{"groupId":"OG001","value":"0.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.2"},{"groupId":"OG001","value":"0.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.2"},{"groupId":"OG001","value":"0.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.2"},{"groupId":"OG001","value":"0.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.2"},{"groupId":"OG001","value":"0.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.2"},{"groupId":"OG001","value":"0.0","spread":"0.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.2"},{"groupId":"OG001","value":"0.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.2"},{"groupId":"OG001","value":"0.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.2"},{"groupId":"OG001","value":"0.1","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.3"},{"groupId":"OG001","value":"-0.1","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.2"},{"groupId":"OG001","value":"-0.1","spread":"0.3"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":79,"n":139},"commonTop":["Thrombocytopenia","Diarrhoea","Anaemia","Fatigue","Cough"]}}}